A5082366310- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Retinoids in leukemia and cellular processes
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Advanced Breast Cancer Therapies
- Lysosomal Storage Disorders Research
- CNS Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Hemoglobinopathies and Related Disorders
- Retinal Diseases and Treatments
- Drug-Induced Ocular Toxicity
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Trypanosoma species research and implications
- Protein Degradation and Inhibitors
- Cancer, Lipids, and Metabolism
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
Hospital Universitario 12 De Octubre
2016-2025
Research Institute Hospital 12 de Octubre
2014-2025
Empresarios Agrupados
2024
Nicolaus Copernicus University
2021
Hospital Universitario HM Madrid
2020
Hudson Institute
2020
John Wiley & Sons (United States)
2020
Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2018
Universitat Autònoma de Barcelona
2013
Spanish Society of Hematology and Hemotherapy
2000-2011
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients previously untreated chronic lymphocytic leukemia (CLL) but not those coexisting conditions. We investigated the benefit of type 2, glycoengineered obinutuzumab (also known as GA101) compared that each chlorambucil, CLL and conditions.We randomly assigned 781 a score higher than 6 on Cumulative Illness Rating Scale (CIRS) (range, 0 56,...
Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and central to the survival of chronic lymphocytic leukemia cells. We evaluated efficacy venetoclax in combination with rituximab patients relapsed or refractory leukemia.In this randomized, open-label, phase 3 trial, we randomly assigned 389 receive for up 2 years (from day 1 cycle 1) plus first 6 months (venetoclax-rituximab group) bendamustine (bendamustine-rituximab group). The trial design did not...
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). METHODS Eligible patients, aged ≥ 18 years R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative Oncology Group performance status score, number of prior lines therapy. Patients received acalabrutinib...
<h3>Importance</h3> Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. <h3>Objective</h3> To assess the efficacy and adverse event profile of in immunocompromised HSCT recipients. <h3>Design, Setting, Participants</h3> Phase 3, randomized, observer-blinded study conducted 167 centers 28...
In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine (BR) patients relapsed or refractory chronic lymphocytic leukemia (CLL). At 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and predictive value molecular genetic characteristics.Patients CLL were randomly assigned 2 years (VenR for first six cycles) cycles BR. PFS, overall (OS),...
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine in Participants Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) relapsed/refractory (R/R) CLL. Patients were randomized 2 years VenR (n = 194; rituximab for first 6 months) months BR 195). Although...
PURPOSE: To analyze clinical outcome and significant prognostic factors for overall (OS) time to treatment failure (TTF) in a group of 494 patients with Hodgkin’s disease (HD) undergoing autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: Detailed records from the Grupo Español de Linfomas/Transplante Autólogo Médula Ósea Spanish Cooperative Group Database on HD who received an ASCT between January 1984 May 1998 were reviewed. Two hundred ninety-eight males 196 females median...
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility there is no consensus the role of new markers. aim this project was to identify reproducible markers recommended diagnosis CLL. ERIC/ESCCA members classified 14 35 potential as “required” or “recommended” diagnosis, being defined >75% >50% agreement, respectively. An approach validate using normal peripheral blood developed. Responses were received from...
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND the pivotal phase 3 study of acalabrutinib versus investigator's choice idelalisib plus rituximab (IdR) or bendamustine (BR) in relapsed/refractory (R/R) CLL. In primary analysis (median 16.1-month follow-up), showed superior efficacy an acceptable tolerability profile IdR/BR; here, we report final ~4 year follow-up results. Patients R/R CLL received oral 100 mg twice...
We report the results of reduced-intensity conditioning allogeneic stem cell transplantation (allo-RIC) in patients with advanced Hodgkin lymphoma (HL). Forty relapsed or refractory HL were homogeneously treated an RIC protocol (fludarabine 150 mg/m(2) intravenously plus melphalan 140 intravenously) and cyclosporin A methotrexate as graft-versus-host disease (GVHD) prophylaxis. Twenty-one (53%) had received >2 lines chemotherapy, 23 (58%) radiotherapy, 29 (73%) experienced treatment failure...
To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologous or allogeneic stem-cell transplantation (SCT) during second complete remission.Of 122 relapsing included in two successive multicenter APL trials achieved hematological remission (generally after a salvage regimen all-trans-retinoic acid [ATRA] combined with chemotherapy), 73 (60%) received (n = 23) 50) SCT.Seven-year relapse-free survival (RFS), event-free (EFS), and overall (OS)...
To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia (CLL) and/or high-risk molecular/cytogenetic characteristics.Eighty-three percent had active disease at moment transplant. That is, 14 23 analyzed (60%) unmutated immunoglobulin variable heavy-chain gene (IgV(H)) status; 8 25 (32%) 11q-, four them also displaying IgV(H); and six (24%) 17p- (five were unmutated).After a median follow-up 47.3...
To analyze the simultaneous combination of all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for children with acute promyelocytic leukemia (APL).Since November 1996, 66 (younger than 18 years) genetically proven APL received induction therapy ATRA idarubicin. Consolidation consisted three courses monochemotherapy. After 1999, patients intermediate high risk relapse consolidation slightly reinforced doses Maintenance low-dose mercaptopurine methotrexate.Thirty-nine girls...
Purpose To determine the results of treatment combining all-trans-retinoic acid (ATRA) and chemotherapy (CT) in childhood acute promyelocytic leukemia (APL). Patients Methods Children (< 18 years) with newly diagnosed APL were included APL93 trial, treated by ATRA followed or combined daunorubicin-cytarabine, then randomly assigned between no maintenance, intermittent ATRA, continuous CT, both. Results Of 576 patients 31 (5%) children, including 22 girls (71%) nine boys (29%). Thirty...
Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established remain a controversial matter.Design Methods Between 1996 2005, 739 newly diagnosed enrolled two consecutive trials (PETHEMA LPA96 LPA99) received induction therapy all-trans retinoic acid idarubicin. Consolidation comprised three courses anthracycline monochemotherapy (LPA96), reinforced doses idarubicin an intermediate or high relapse...